• 1. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 2. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 3. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 4. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 5. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Oxazepines 1,4-oxazepines

Introduction to 2-(propan-2-yl)-1,4-oxazepane (CAS No. 1508439-86-8)

2-(propan-2-yl)-1,4-oxazepane, identified by the Chemical Abstracts Service Number (CAS No.) 1508439-86-8, is a heterocyclic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal biology. This compound belongs to the oxazepane class, a structural motif characterized by a seven-membered ring containing two oxygen atoms and one nitrogen atom. The presence of an isopropyl substituent at the 2-position of the oxazepane ring introduces unique electronic and steric properties, making it a promising candidate for further exploration in drug discovery and development.

The structure of 2-(propan-2-yl)-1,4-oxazepane exhibits a high degree of molecular complexity, which is often exploited to modulate biological activity. Oxazepanes are known for their potential as pharmacophores in various therapeutic areas, including central nervous system (CNS) disorders, antipsychotics, and anti-anxiety agents. The isopropyl group at the 2-position enhances the compound's lipophilicity, facilitating better membrane penetration and potentially improving oral bioavailability—a critical factor in drug formulation.

Recent advancements in computational chemistry and molecular modeling have allowed researchers to predict the binding affinity of 2-(propan-2-yl)-1,4-oxazepane to various biological targets. Studies suggest that this compound may interact with serotonin receptors (e.g., 5-HT1A), which are implicated in mood regulation and anxiety disorders. The flexible nature of the oxazepane ring provides a scaffold that can be further modified to optimize receptor binding while minimizing off-target effects.

In parallel, experimental investigations have begun to unravel the pharmacokinetic profile of CAS No. 1508439-86-8. Initial studies indicate that the compound exhibits moderate solubility in water and good stability under physiological conditions, suggesting its feasibility for pharmaceutical applications. Additionally, preliminary toxicity assessments have shown no significant adverse effects at tested doses, paving the way for more extensive preclinical evaluations.

The synthesis of 2-(propan-2-yl)-1,4-oxazepane has been optimized through multi-step organic reactions involving cyclization and alkylation processes. Modern synthetic methodologies, such as transition-metal-catalyzed cross-coupling reactions, have been employed to enhance yield and purity. These advancements not only streamline production but also allow for rapid diversification of the oxazepane core, enabling the generation of libraries of derivatives for high-throughput screening.

One of the most intriguing aspects of this compound is its potential role in addressing neurological disorders. Oxazepane derivatives have been investigated for their ability to modulate GABAergic pathways, which are central to neuronal inhibition. The isopropyl substituent, in particular, may influence the compound's interaction with GABA(A) receptors, potentially leading to novel therapeutic interventions for conditions such as epilepsy or chronic pain.

Furthermore, recent research has highlighted the pharmacological significance of oxazepanes in oncology. Studies suggest that certain derivatives exhibit inhibitory effects on kinases involved in cancer cell proliferation. While CAS No. 1508439-86-8 itself has not yet been tested in oncological models, its structural features make it a valuable starting point for designing molecules with enhanced anticancer properties.

The integration of machine learning algorithms into drug discovery has accelerated the identification of promising candidates like 2-(propan-2-yl)-1,4-oxazepane. Predictive models trained on large datasets have ranked this compound among top hits for several disease targets, prompting further investigation into its biological activity. Such computational approaches not only save time but also provide insights into structural modifications that could enhance efficacy.

As interest in heterocyclic compounds continues to grow, this oxazepane derivative represents a significant area of exploration within medicinal chemistry. Its unique structural features and demonstrated preclinical potential position it as a cornerstone for future research efforts aimed at developing next-generation therapeutics.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)